

# Eric J Arts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4732255/publications.pdf>

Version: 2024-02-01

132  
papers

5,731  
citations

76196

40  
h-index

88477

70  
g-index

142  
all docs

142  
docs citations

142  
times ranked

5933  
citing authors

#	ARTICLE	IF	CITATIONS
1	“So that’s why we hide, we don’t want them to know” challenges to antiretroviral therapy adherence in Kampala, Uganda. <i>African Geographical Review</i> , 2024, 43, 18-31.	0.6	0
2	Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope. <i>Journal of Virology</i> , 2022, 96, .	1.5	1
3	Failure is not an option: Barriers to HIV treatment adherence in Kampala, Uganda. <i>Health and Place</i> , 2021, 67, 102481.	1.5	2
4	Deep Gene Sequence Cluster Analyses of Multi-Virus-Infected Mucosal Tissue Reveal Enhanced Transmission of Acute HIV-1. <i>Journal of Virology</i> , 2021, 95, .	1.5	1
5	Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings. <i>International Journal of Infectious Diseases</i> , 2021, 105, 298-303.	1.5	14
6	An Amino Acid Polymorphism within the HIV-1 Nef Dileucine Motif Functionally Uncouples Cell Surface CD4 and SERINC5 Downregulation. <i>Journal of Virology</i> , 2021, 95, e0058821.	1.5	6
7	Addressing an HIV cure in LMIC. <i>Retrovirology</i> , 2021, 18, 21.	0.9	8
8	High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2965-2974.	1.3	13
9	A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2. <i>PLoS Pathogens</i> , 2021, 17, e1010092.	2.1	12
10	A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection. <i>EBioMedicine</i> , 2020, 59, 102853.	2.7	12
11	Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3525-3533.	1.3	12
12	The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030. <i>Infectious Diseases of Poverty</i> , 2019, 8, 63.	1.5	25
13	First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda. <i>AIDS Research and Therapy</i> , 2019, 16, 3.	0.7	8
14	Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance. <i>Heliyon</i> , 2019, 5, e01498.	1.4	15
15	Heating Injection Drug Preparation Equipment Used for Opioid Injection May Reduce HIV Transmission Associated With Sharing Equipment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e127-e134.	0.9	14
16	An ultra-high affinity ligand of HIV-1 TAR reveals the RNA structure recognized by P-TEFb. <i>Nucleic Acids Research</i> , 2019, 47, 1523-1531.	6.5	37
17	Evolution-Guided Structural and Functional Analyses of the HERC Family Reveal an Ancient Marine Origin and Determinants of Antiviral Activity. <i>Journal of Virology</i> , 2018, 92, .	1.5	29
18	A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. <i>Npj Vaccines</i> , 2018, 3, 2.	2.9	17

#	ARTICLE	IF	CITATIONS
19	Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 404-414.	0.5	23
20	Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection. <i>PLoS Pathogens</i> , 2018, 14, e1006754.	2.1	16
21	An in vitro Model to Mimic Selection of Replication-Competent HIV-1 Intersubtype Recombination in Dual or Superinfected Patients. <i>Journal of Molecular Biology</i> , 2017, 429, 2246-2264.	2.0	5
22	Dr. Mark A. Wainberg (1945â€“2017): Provocateur, Activist, and Champion for AIDS Care and Research. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, iii-iv.	0.5	0
23	Tribute to Mark Wainberg. <i>Retrovirology</i> , 2017, 14, 38.	0.9	0
24	Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. <i>AIDS Research and Therapy</i> , 2017, 14, 55.	0.7	20
25	Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries. <i>Infectious Diseases of Poverty</i> , 2017, 6, 163.	1.5	11
26	HIV-1 Entry and Fusion Inhibitors: Mechanisms and Resistance. , 2017, , 545-557.		1
27	Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3380-3397.	1.4	49
28	First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. <i>Retrovirology</i> , 2016, 13, 82.	0.9	21
29	Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections. <i>Virology</i> , 2016, 499, 298-312.	1.1	4
30	Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa. <i>EBioMedicine</i> , 2016, 13, 305-314.	2.7	74
31	A Highly Conserved Residue in HIV-1 Nef Alpha Helix 2 Modulates Protein Expression. <i>MSphere</i> , 2016, 1, .	1.3	12
32	Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. <i>AIDS Research and Therapy</i> , 2016, 13, 41.	0.7	3
33	HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 676-688.	0.5	10
34	Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing. <i>International Journal of Stem Cell Research and Therapy</i> , 2016, 3, .	1.0	6
35	Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage. <i>AIDS Research and Therapy</i> , 2015, 12, 34.	0.7	6
36	Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants. <i>Retrovirology</i> , 2015, 12, 44.	0.9	4

#	ARTICLE	IF	CITATIONS
37	SiRNA-Induced Mutation in HIV-1 Polypurine Tract Region and Its Influence on Viral Fitness. <i>PLoS ONE</i> , 2015, 10, e0122953.	1.1	2
38	Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. <i>Journal of Virology</i> , 2015, 89, 7521-7535.	1.5	20
39	Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 415-422.	0.6	7
40	Comparison of Antibody Responses to HIV Infection in Ugandan Women Infected with HIV Subtypes A and D. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 421-427.	0.5	16
41	Similar Replicative Fitness Is Shared by the Subtype B and Unique BF Recombinant HIV-1 Isolates that Dominate the Epidemic in Argentina. <i>PLoS ONE</i> , 2014, 9, e92084.	1.1	12
42	From Simian to Human Immunodeficiency Viruses (SIV to HIV). , 2014, , 201-234.		1
43	Immune Responses in Ugandan Women Infected With Subtypes A and D HIV Using the BED Capture Immunoassay and an Antibody Avidity Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 390-396.	0.9	15
44	Impact of Mutations in Highly Conserved Amino Acids of the HIV-1 Gag-p24 and Env-gp120 Proteins on Viral Replication in Different Genetic Backgrounds. <i>PLoS ONE</i> , 2014, 9, e94240.	1.1	18
45	HIV-1 Resistance to Maraviroc Conferred by a CD4 Binding Site Mutation in the Envelope Glycoprotein gp120. <i>Journal of Virology</i> , 2013, 87, 923-934.	1.5	48
46	A cis-Acting Element in Retroviral Genomic RNA Links Gag-Pol Ribosomal Frameshifting to Selective Viral RNA Encapsidation. <i>Cell Host and Microbe</i> , 2013, 13, 181-192.	5.1	39
47	Mucosal Tissue Tropism and Dissemination of HIV-1 Subtype B Acute Envelope-Expressing Chimeric Virus. <i>Journal of Virology</i> , 2013, 87, 890-899.	1.5	23
48	Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1517-1527.	1.8	18
49	Multifaceted Mechanisms of HIV Inhibition and Resistance to CCR5 Inhibitors PSC-RANTES and Maraviroc. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2640-2650.	1.4	13
50	Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. <i>Aids</i> , 2013, 27, 1899-1909.	1.0	33
51	Past, Present, and Future of Entry Inhibitors as HIV Microbicides. <i>Current HIV Research</i> , 2012, 10, 19-26.	0.2	21
52	Effect of Natural Polymorphisms in the HIV-1 CRF02_AG Protease on Protease Inhibitor Hypersusceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2719-2725.	1.4	11
53	HIV-1 Antiretroviral Drug Therapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007161-a007161.	2.9	613
54	A hybrid stochastic-deterministic computational model accurately describes spatial dynamics and virus diffusion in HIV-1 growth competition assay. <i>Journal of Theoretical Biology</i> , 2012, 312, 120-132.	0.8	10

#	ARTICLE	IF	CITATIONS
55	Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication. <i>BMC Medicine</i> , 2012, 10, 114.	2.3	4
56	Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism. <i>PLoS ONE</i> , 2012, 7, e49602.	1.1	78
57	Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 45-56.	4.6	212
58	HIV-1 replicative fitness in elite controllers. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 214-220.	1.5	37
59	Hormonal Contraceptive Use and HIV Disease Progression Among Women in Uganda and Zimbabwe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 157-164.	0.9	38
60	Enrichment of intersubtype HIV-1 recombinants in a dual infection system using HIV-1 strain-specific siRNAs. <i>Retrovirology</i> , 2011, 8, 5.	0.9	6
61	Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3 $\alpha$ Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3729-3742.	1.4	23
62	Inhibition of Both HIV-1 Reverse Transcription and Gene Expression by a Cyclic Peptide that Binds the Tat-Transactivating Response Element (TAR) RNA. <i>PLoS Pathogens</i> , 2011, 7, e1002038.	2.1	66
63	Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. <i>Aids</i> , 2010, 24, 573-582.	1.0	76
64	Divergent Evolution in Reverse Transcriptase (RT) of HIV-1 Group O and M Lineages: Impact on Structure, Fitness, and Sensitivity to Nonnucleoside RT Inhibitors. <i>Journal of Virology</i> , 2010, 84, 9817-9830.	1.5	25
65	HIV-1 Entry, Inhibitors, and Resistance. <i>Viruses</i> , 2010, 2, 1069-1105.	1.5	56
66	DNA Suspension Arrays: Silencing Discrete Artifacts for High-Sensitivity Applications. <i>PLoS ONE</i> , 2010, 5, e15476.	1.1	4
67	A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. <i>BioTechniques</i> , 2009, 46, 458-467.	0.8	39
68	CCR5- and CXCR4-Tropic Subtype C Human Immunodeficiency Virus Type 1 Isolates Have a Lower Level of Pathogenic Fitness than Other Dominant Group M Subtypes: Implications for the Epidemic. <i>Journal of Virology</i> , 2009, 83, 5592-5605.	1.5	86
69	Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009, 21, 271-279.	0.6	72
70	Selection of a Simian-Human Immunodeficiency Virus Strain Resistant to a Vaginal Microbicide in Macaques. <i>Journal of Virology</i> , 2009, 83, 5067-5076.	1.5	25
71	HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphocyte Recognition. <i>Journal of Virology</i> , 2009, 83, 2743-2755.	1.5	261
72	Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 938-944.	1.3	12

#	ARTICLE	IF	CITATIONS
73	Elite Suppressorâ€œDerived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics. PLoS Pathogens, 2009, 5, e1000377.	2.1	93
74	Variable Fitness Impact of HIV-1 Escape Mutations to Cytotoxic T Lymphocyte (CTL) Response. PLoS Pathogens, 2009, 5, e1000365.	2.1	169
75	Adherence and Treatment Response Among HIV-1-Infected Adults Receiving Antiretroviral Therapy in a Rural Government Hospital in Southwestern Uganda. Journal of the International Association of Providers of AIDS Care, 2009, 8, 139-147.	1.2	39
76	A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains. Journal of Virology, 2009, 83, 11016-11026.	1.5	84
77	The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART. AIDS Reviews, 2009, 11, 59-70.	0.5	10
78	Viral Drug Resistance and Fitness. Advances in Pharmacology, 2008, 56, 257-296.	1.2	30
79	A Radiolabeled Oligonucleotide Ligation Assay Demonstrates the High Frequency of Nevirapine Resistance Mutations in HIV Type 1 Quasispecies of NVP-Treated and Untreated Motherâ€œInfant Pairs from Uganda. AIDS Research and Human Retroviruses, 2008, 24, 235-250.	0.5	17
80	Identifying the Important HIV-1 Recombination Breakpoints. PLoS Computational Biology, 2008, 4, e1000178.	1.5	58
81	Targets of Small Interfering RNA Restriction during Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 2008, 82, 2938-2951.	1.5	20
82	Molecular Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B. Journal of Clinical Microbiology, 2008, 46, 177-184.	1.8	50
83	Calculating HIV-1 Infectious Titre Using a Virtual TCID50 Method. Methods in Molecular Biology, 2008, 485, 27-35.	0.4	16
84	Evolution of Human Immunodeficiency Virus Type 1 Cytotoxic T-Lymphocyte Epitopes: Fitness-Balanced Escape. Journal of Virology, 2007, 81, 12179-12188.	1.5	72
85	Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness Loss. PLoS Pathogens, 2007, 3, e79.	2.1	43
86	Natural Variation in the V3 Crown of Human Immunodeficiency Virus Type 1 Affects Replicative Fitness and Entry Inhibitor Sensitivity. Journal of Virology, 2007, 81, 8258-8269.	1.5	49
87	Sensitive Oligonucleotide Ligation Assay for Low-Level Detection of Nevirapine Resistance Mutations in Human Immunodeficiency Virus Type 1 Quasispecies. Journal of Clinical Microbiology, 2007, 45, 2604-2615.	1.8	25
88	Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations. Current Opinion in HIV and AIDS, 2007, 2, 81-87.	1.5	7
89	Is HIV-1 evolving to a less virulent form in humans?. Nature Reviews Microbiology, 2007, 5, 141-151.	13.6	164
90	The impact of viral and host elements on HIV fitness and disease progression. Current HIV/AIDS Reports, 2007, 4, 36-41.	1.1	5

#	ARTICLE	IF	CITATIONS
91	HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle?. <i>AIDS Reviews</i> , 2007, 9, 75-87.	0.5	73
92	Influence of sequence identity and unique breakpoints on the frequency of intersubtype HIV-1 recombination. <i>Retrovirology</i> , 2006, 3, 91.	0.9	30
93	Sequence determinants of breakpoint location during HIV-1 intersubtype recombination. <i>Nucleic Acids Research</i> , 2006, 34, 5203-5216.	6.5	53
94	Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. <i>Aids</i> , 2005, 19, 1555-1564.	1.0	70
95	Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. <i>AIDS Research and Therapy</i> , 2005, 2, 2.	0.7	1
96	The Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 (HIV-1) Group M, HIV-1 Group O, and HIV-2 Isolates. <i>Journal of Virology</i> , 2005, 79, 8979-8990.	1.5	179
97	Methods to Determine HIV-1 Ex Vivo Fitness. , 2005, 304, 355-368.		15
98	A Yeast Recombination-Based Cloning System to Produce Chimeric HIV-1 Viruses and Express HIV-1 Genes. , 2005, 304, 369-386.		8
99	Differences in the Fitness of Two Diverse Wild-Type Human Immunodeficiency Virus Type 1 Isolates Are Related to the Efficiency of Cell Binding and Entry. <i>Journal of Virology</i> , 2005, 79, 7121-7134.	1.5	92
100	Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression. <i>Journal of Virology</i> , 2005, 79, 9006-9018.	1.5	182
101	Relationships between Infectious Titer, Capsid Protein Levels, and Reverse Transcriptase Activities of Diverse Human Immunodeficiency Virus Type 1 Isolates. <i>Journal of Virology</i> , 2004, 78, 11130-11141.	1.5	92
102	Characterization of a Subtype D Human Immunodeficiency Virus Type 1 Isolate That Was Obtained from an Untreated Individual and That Is Highly Resistant to Nonnucleoside Reverse Transcriptase Inhibitors. <i>Journal of Virology</i> , 2004, 78, 5390-5401.	1.5	29
103	PSC-RANTES Blocks R5 Human Immunodeficiency Virus Infection of Langerhans Cells Isolated from Individuals with a Variety of CCR5 Diplotypes. <i>Journal of Virology</i> , 2004, 78, 7602-7609.	1.5	64
104	High Prevalence of Antiretroviral Resistance in Treated Ugandans Infected with Non-subtype B Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 355-364.	0.5	53
105	Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda. <i>African Health Sciences</i> , 2004, 4, 146-54.	0.3	8
106	Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. <i>Journal of Virological Methods</i> , 2003, 111, 111-120.	1.0	26
107	Comparing the Ex Vivo Fitness of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates of Subtypes B and C. <i>Journal of Virology</i> , 2003, 77, 1021-1038.	1.5	189
108	Sorting out the complexities of HIV-1 fitness. <i>Aids</i> , 2003, 17, 780-781.	1.0	15

#	ARTICLE	IF	CITATIONS
109	Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa. <i>Journal of the National Cancer Institute</i> , 2002, 94, 718-732.	3.0	17
110	Human Immunodeficiency Virus Type 1 (HIV-1) Quasispecies at the Sites of Mycobacterium tuberculosis Infection Contribute to Systemic HIV-1 Heterogeneity. <i>Journal of Virology</i> , 2002, 76, 1697-1706.	1.5	66
111	In Vitro Intersubtype Recombinants of Human Immunodeficiency Virus Type 1: Comparison to Recent and Circulating In Vivo Recombinant Forms. <i>Journal of Virology</i> , 2002, 76, 9600-9613.	1.5	51
112	Fitness of drug resistant HIV-1: methodology and clinical implications. <i>Drug Resistance Updates</i> , 2002, 5, 224-233.	6.5	82
113	Functional Characterization of Chimeric Reverse Transcriptases with Polypeptide Subunits of Highly Divergent HIV-1 Group M and O Strains. <i>Journal of Biological Chemistry</i> , 2001, 276, 27470-27479.	1.6	32
114	Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminooxypentane RANTES. <i>Journal of Virology</i> , 2001, 75, 8624-8638.	1.5	40
115	Greater Diversity of HIV-1 Quasispecies in HIV-Infected Individuals With Active Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 408-417.	0.9	16
116	Crossing the resistance divide. <i>Nature</i> , 2000, 407, 300-300.	13.7	0
117	A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression. <i>Journal of Virology</i> , 2000, 74, 9222-9233.	1.5	224
118	Greater Diversity of HIV-1 Quasispecies in HIV-Infected Individuals With Active Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 408-417.	0.9	34
119	Quantitation of Human Immunodeficiency Virus Type 1 Group O Load in Plasma by Measuring Reverse Transcriptase Activity. <i>Journal of Clinical Microbiology</i> , 2000, 38, 402-405.	1.8	12
120	Molecular Epidemiology of HIV Type 1 Isolates from the Czech Republic: Identification of an env E Subtype Case. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 85-89.	0.5	11
121	Mechanisms of clinical resistance by HIV-1 variants to zidovudine and the paradox of reverse transcriptase sensitivity. <i>Drug Resistance Updates</i> , 1998, 1, 21-28.	6.5	11
122	Mutating a Region of HIV-1 Reverse Transcriptase Implicated in tRNA <sup>Lys</sup> -3 Binding and the Consequences for (âˆš)-Strand DNA Synthesis. <i>Journal of Biological Chemistry</i> , 1998, 273, 14523-14532.	1.6	18
123	Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1998, 72, 9002-9015.	1.5	64
124	3â€™-Azido-2-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants. <i>Journal of Virology</i> , 1998, 72, 4858-4865.	1.5	21
125	Interaction of Retroviral Reverse Transcriptase with Template-Primer Duplexes during Replication. <i>Progress in Molecular Biology and Translational Science</i> , 1997, 58, 339-393.	1.9	75
126	Involvement of C-terminal Structural Elements of Equine Infectious Anemia Virus Reverse Transcriptase in DNA Polymerase and Ribonuclease H Activities. <i>Journal of Molecular Biology</i> , 1996, 257, 500-511.	2.0	18



#	ARTICLE	IF	CITATIONS
127	Multiple Forms of tRNA <sup>Lys3</sup> in HIV-1. <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 530-540.	1.0	9
128	Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Early Events in Reverse Transcription. <i>Advances in Virus Research</i> , 1996, 46, 97-163.	0.9	63
129	Restoration of tRNA <sup>Lys</sup> -primed (-) Strand DNA Synthesis to an HIV-1 Reverse Transcriptase Mutant with Extended tRNAs. <i>Journal of Biological Chemistry</i> , 1996, 271, 9054-9061.	1.6	95
130	Analysis of primer extension and the first template switch during human immunodeficiency virus reverse transcription. <i>Journal of Biomedical Science</i> , 1995, 2, 314-321.	2.6	16
131	Effects of Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 in Cell-free Recombinant Reverse Transcriptase Assays. <i>Journal of Biological Chemistry</i> , 1995, 270, 31046-31051.	1.6	74
132	Infection of human monocyte-derived macrophages by human immunodeficiency virus mediated by cell-to-cell transmission. <i>Journal of Medical Virology</i> , 1993, 41, 71-78.	2.5	12